Smith Moore & CO. Increases Stake in iShares NASDAQ Biotechnology Index (IBB)

Smith Moore & CO. increased its position in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 200.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,422 shares of the financial services provider’s stock after buying an additional 2,283 shares during the period. Smith Moore & CO.’s holdings in iShares NASDAQ Biotechnology Index were worth $365,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Citizens Financial Group Inc RI grew its stake in iShares NASDAQ Biotechnology Index by 191.7% in the fourth quarter. Citizens Financial Group Inc RI now owns 5,259 shares of the financial services provider’s stock valued at $562,000 after purchasing an additional 3,456 shares during the last quarter. FDx Advisors Inc. grew its stake in iShares NASDAQ Biotechnology Index by 76.2% in the fourth quarter. FDx Advisors Inc. now owns 2,495 shares of the financial services provider’s stock valued at $266,000 after purchasing an additional 1,079 shares during the last quarter. Synovus Financial Corp grew its stake in iShares NASDAQ Biotechnology Index by 192.3% in the fourth quarter. Synovus Financial Corp now owns 200,927 shares of the financial services provider’s stock valued at $21,458,000 after purchasing an additional 132,194 shares during the last quarter. Honkamp Krueger Financial Services Inc. grew its stake in iShares NASDAQ Biotechnology Index by 66.5% in the fourth quarter. Honkamp Krueger Financial Services Inc. now owns 2,852 shares of the financial services provider’s stock valued at $305,000 after purchasing an additional 1,139 shares during the last quarter. Finally, D L Carlson Investment Group Inc. grew its stake in iShares NASDAQ Biotechnology Index by 200.5% in the fourth quarter. D L Carlson Investment Group Inc. now owns 40,740 shares of the financial services provider’s stock valued at $4,350,000 after purchasing an additional 27,182 shares during the last quarter. Hedge funds and other institutional investors own 38.31% of the company’s stock.

iShares NASDAQ Biotechnology Index (NASDAQ IBB) opened at $110.36 on Tuesday. iShares NASDAQ Biotechnology Index has a 52 week low of $94.20 and a 52 week high of $119.30. The stock has a market capitalization of $9,670.00, a PE ratio of 3.64 and a beta of 1.37.

COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/20/smith-moore-co-increases-stake-in-ishares-nasdaq-biotechnology-index-ibb.html.

iShares NASDAQ Biotechnology Index Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply